A COST-EFFECTIVENESS ANALYSIS OF THE ZIRA TEST IN BREAST CANCER
Carole Siani, Lionel Perrier, Christian de Peretti(Université Claude Bernard Lyon 1), Thomas Bachelot(Centre Léon Bérard), Julie A. Vendrell(Inserm), N. Plommet, Pascale A. Cohen(Lyon 1 Université), Balázs Győrffy(Semmelweis University)
Cited by 0
Related Papers
Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
|PLoS ONE|2013|1.9k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
|Annals of Oncology|2021|577
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
|The Lancet Oncology|2014|410
Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors
|Endocrine Reviews|2011|302